Abstract
The carbonic anhydrase (CA) family has recently become an important target for the drug design of inhibitors with potential use as diagnostic and therapeutic tools. However, given the high degree of sequence and structure similarity among the different CA isoforms, no CA-directed drug developed so far has displayed selectivity for a specific isozyme. Since X-Ray crystallography is a very useful tool for the rational drug design of selective enzyme inhibitors, in recent years extensive research efforts have been devoted to the structural studies of all catalytically active α-CA isoforms, with the consequent resolution of the crystallographic structures of nearly all such enzyme isoforms. In this paper we review the progress that has recently been made in this field. In particular, we summarize the main structural features of hCA XIII and hCA IX, the most recently characterized human CA isoforms, and recapitulate how 3D structures of these enzymes, together with kinetic experiments, have been used either to deepen our knowledge on the structural features responsible of the catalytic properties of this protein family or to obtain important information for the rational drug design of inhibitors with better selectivity properties.
Keywords: Carbonic Anhydrase IX, Carbonic Anhydrase XIII, inhibitor, structure based drug design, crystal structure, carbonic anhydrase (CA), isozyme, X-Ray crystallography, 3D structures, ubiquitous metallo-enzymes, CA inhibitors (CAIs), diuretics, antiglaucoma, antiepileptics, submandibular gland, Cytosolic CA Isozymes, mutagenesis, HUMAN CA IX, transmembrane segment (TM), intracytoplasmic (IC) portion, N-terminal proteoglycan, disulfide bond, Mass spectrometry, hypoxic phenotype, anion exchangers (AEs), Na+/bicarbonate cotransporters (NBCs), apoptosis, tumor cells, anticonvulsants, spermatogenesis, Carbonic anhydrase, Human CA, Murine CA, Hypoxia inducible factor, Hypoxia response elements, Anion exchanger, Na+/bicarbonate cotransporter, Transmembrane, Intracytoplasmic, Proteoglycan-like domain
Current Pharmaceutical Design
Title: Recent Advances in Structural Studies of the Carbonic Anhydrase Family: The Crystal Structure of Human CA IX and CA XIII
Volume: 16 Issue: 29
Author(s): Claudiu T. Supuran, Anna Di Fiore, Vincenzo Alterio, Simona Maria Monti and Giuseppina De Simone
Affiliation:
Keywords: Carbonic Anhydrase IX, Carbonic Anhydrase XIII, inhibitor, structure based drug design, crystal structure, carbonic anhydrase (CA), isozyme, X-Ray crystallography, 3D structures, ubiquitous metallo-enzymes, CA inhibitors (CAIs), diuretics, antiglaucoma, antiepileptics, submandibular gland, Cytosolic CA Isozymes, mutagenesis, HUMAN CA IX, transmembrane segment (TM), intracytoplasmic (IC) portion, N-terminal proteoglycan, disulfide bond, Mass spectrometry, hypoxic phenotype, anion exchangers (AEs), Na+/bicarbonate cotransporters (NBCs), apoptosis, tumor cells, anticonvulsants, spermatogenesis, Carbonic anhydrase, Human CA, Murine CA, Hypoxia inducible factor, Hypoxia response elements, Anion exchanger, Na+/bicarbonate cotransporter, Transmembrane, Intracytoplasmic, Proteoglycan-like domain
Abstract: The carbonic anhydrase (CA) family has recently become an important target for the drug design of inhibitors with potential use as diagnostic and therapeutic tools. However, given the high degree of sequence and structure similarity among the different CA isoforms, no CA-directed drug developed so far has displayed selectivity for a specific isozyme. Since X-Ray crystallography is a very useful tool for the rational drug design of selective enzyme inhibitors, in recent years extensive research efforts have been devoted to the structural studies of all catalytically active α-CA isoforms, with the consequent resolution of the crystallographic structures of nearly all such enzyme isoforms. In this paper we review the progress that has recently been made in this field. In particular, we summarize the main structural features of hCA XIII and hCA IX, the most recently characterized human CA isoforms, and recapitulate how 3D structures of these enzymes, together with kinetic experiments, have been used either to deepen our knowledge on the structural features responsible of the catalytic properties of this protein family or to obtain important information for the rational drug design of inhibitors with better selectivity properties.
Export Options
About this article
Cite this article as:
T. Supuran Claudiu, Di Fiore Anna, Alterio Vincenzo, Maria Monti Simona and De Simone Giuseppina, Recent Advances in Structural Studies of the Carbonic Anhydrase Family: The Crystal Structure of Human CA IX and CA XIII, Current Pharmaceutical Design 2010; 16 (29) . https://dx.doi.org/10.2174/138161210793429841
DOI https://dx.doi.org/10.2174/138161210793429841 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Predictive Biomarkers and Novel Targets in the Treatment of Metastatic Renal Cell Carcinoma
Current Medicinal Chemistry Immunophilins: Structures, Mechanisms and Ligands
Current Molecular Pharmacology The HOX Genes Network in Uro-Genital Cancers: Mechanisms and Potential Therapeutic Implications
Current Medicinal Chemistry The Clinical Characteristics and Survival Profiles of Wilms Tumor in the United Arab Emirates: A Single-center Retrospective Analysis
New Emirates Medical Journal Better Targeting Melanoma: Options Beyond Surgery and Conventional Chemotherapy
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Interleukin 2 in Cancer Therapy
Current Medicinal Chemistry Biomarkers for VEGF-Targeted Therapy in Renal Cell Carcinoma: Critical Review of Level of Evidence and Up to Date
Recent Patents on Biomarkers Nuclear Export Mediated Regulation of MicroRNAs: Potential Target for Drug Intervention
Current Drug Targets Natural Products as Exquisitely Potent Cytotoxic Payloads for Antibody- Drug Conjugates
Current Topics in Medicinal Chemistry Toxicities of Targeted Agents in Advanced Renal Cell Carcinoma
Current Clinical Pharmacology Hereditary Papillary Renal Carcinoma Type I
Current Molecular Medicine TGF-β Pathway as a Therapeutic Target in Bone Metastases
Current Pharmaceutical Design LncRNA as a Therapeutic Target for Angiogenesis
Current Topics in Medicinal Chemistry Genistein Inhibits Cell Growth and Invasion Through Regulation of miR-27a in Pancreatic Cancer Cells
Current Pharmaceutical Design Recent Advances in Developing Photosensitizers for Photodynamic Cancer Therapy
Combinatorial Chemistry & High Throughput Screening Tumor Suppression by DNA Base Excision Repair
Mini-Reviews in Medicinal Chemistry Metabolomics-based Approach to Pharmacotherapy Personalization: Advantages and Limitations
Current Pharmacogenomics and Personalized Medicine Metal Containing Cytostatics and Their Interaction with Cellular Thiol Compounds Causing Chemoresistance
Anti-Cancer Agents in Medicinal Chemistry Targeted Radionuclide Therapy - An Overview
Current Radiopharmaceuticals Prognostic and Predictive Biomarkers in Cancer
Current Cancer Drug Targets